Avani Dave, Jai Hind College Ovarian cancer (OC) is among the most devastating gynaecological cancers, with high incidence and mortality rates across the world, putting women’s health and quality of life at risk. Although radical surgery and chemotherapy are two essential treatments for treating OC, they do not appear to diminish the high recurrence rate […]
Srabani Roy Chowdhury (MAKAUT, WB) HGSC or High-Grade Serous Ovarian Carcinoma is considered to be an aggressive type of ovarian cancer. Deleterious mutations present in the DNA repair gene RAD51C are drivers of defective homologous recombination in High-Grade Serous Ovarian Carcinoma (HGSC). These are emerging biomarkers of PARP inhibitor sensitivity. A PARP inhibitor is targeted […]
Avani Dave, Jai Hind College Breast cancer gene BRCA1 has marked its presence as a protein mostly known for being an active contributor in the hereditary associated breast cancer. Apart from being the villain, BRCA1 also plays an indispensable role in the cellular machinery that works towards repairing the double-strand DNA breakage. Recently, researchers from […]
Saakshi Bangera, DY Patil School of Biotechnology and Bioinformatics Ovarian cancer causes a higher mortality rate in women, as compared to other gynaecological cancers. It is characterized by a late presentation and the absence of obvious symptoms. The late diagnosis of ovarian cancer leads to reduced calorie intake and eventually malnutrition. Malnutrition is presumed to […]
Sayak Banerjee, Amity University Kolkata Scientists have come over a class of drugs utilized in the treatment of breast and ovarian cancer which might be effective in other types of diseases with inadequate treatment alternatives. These are called PARP inhibitors which have the potential to kill cancer cells carrying a defect in the Polybromo 1(PBRM1) […]
Chitra Roy, University of Calcutta High-Grade Serous Ovarian Carcinoma (HGSOC) is one of the most common and deadliest types of ovarian cancer. This gynaecological malignancy is a type of tumour which arises from the ovary, fallopian tube, or peritoneum. The tumour microenvironment is very complex and 40% of this tumour mass contains Macrophages. Macrophages originate […]
